



Naproxen's Effect on Performance Within Neuromuscular Parameters

Moises Silvestre de Azevedo Martins ¹, Brad J Schoenfeld ², Gabriel G Zanetti ³, Reury F P Bacurau ⁴ and Sandro Fernandes da Silva ^{1,*}

¹Studies Research Group in Neuromuscular Responses, GEPREN, University of Lavras, Lavras, Brazil

²Department of Health Sciences, CUNY Lehman College, Bronx, New York, United States

³Department of Fundamental Nursing, University of São Paulo, São Paulo, Brazil

⁴Department of Physical Education, University of São Paulo, São Paulo, Brazil

*Corresponding author: Studies Research Group in Neuromuscular Responses Academic, Department of Physical Education, University of Lavras, Lavras Ave., Doutor Sylvio Menicucci, 1001, Kennedy, Postal Code: 37200-000, Lavras, Brazil. Tel/Fax: +55-3538295132, Email: sandrofs@def.ufla.br

Received 2018 June 07; Revised 2019 November 30; Accepted 2019 February 16.

Abstract

This study investigated whether naproxen has an ergogenic effect on neuromuscular performance. A randomized, double-blind, placebo-controlled, crossover trial was conducted on 11 resistance-trained men who performed one strength-training session after taking 500 mg of naproxen and another session after taking a placebo. Participants performed three sets of the horizontal bench press with a load of 90% of repetition maximum (RM) to concentric failure. Outcome variables included number of repetitions, workload, fatigue index (FI), and delayed onset muscle soreness (DOMS). Results showed a statistically insignificant reduction in the number of repetitions for placebo when compared to naproxen, amounting to a relative difference of 44.89%. DOMS was lower in the naproxen group, but differences between conditions were not statistically significant. A statistically significant treatment effect was found for workload, favoring naproxen treatment. A statistically significant difference was found for FI between the second and third sets compared to the first set, with results favoring naproxen. We concluded that naproxen helps enhance neuromuscular outcomes in an acute high-intensity strength training bout.

Keywords: Strength Training, Naproxen, NSAIDs

1. Background

Naproxen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are among the world's most prescribed medications (1) because, primarily, of their anti-inflammatory and analgesic effects (2). Due to these characteristics and because their use is approved by the World Anti-Doping Agency, NSAIDs are regularly consumed by athletes for ergogenic benefit (3-5).

A study analyzing drug and dietary supplement use by 234 athletes participating in South American games reported that 157 consumed some type of medication immediately before or during competition, and 36.9% were NSAIDs (6). The study also found that NSAIDs were the most commonly used drugs because of their well-established role in treatment of musculoskeletal conditions widespread in athletic competitions (6).

Injuries that affect athletes often result from the need to increase muscular strength, which relates directly to performance improvement in numerous sporting events. To improve muscle strength, athletes must exercise at a level that challenges the neuromuscular system suffi-

ciently to promote physiological and structural adaptations (7, 8). However, such training can also bring about tissue damage and inflammation, resulting in delayed onset muscle soreness (DOMS) and a consequent decrease in muscle strength (9). Despite these detrimental effects, it has been proposed that the acute inflammatory response may be a key element in beneficial post-exercise tissue adaptations (10).

In attempts to gain competitive advantage during strength training, athletes use NSAIDs such as ibuprofen, aspirin, naproxen, and others (6). However, whether consumption of these drugs confers a performance-enhancing benefit remains unclear. One study showed that ibuprofen did not alter the number of repetitions performed in upper or lower limbs, indicating that its use did not alter exercise tolerance during a strength-training session (11). Another study found that ibuprofen had no effect on the histologic appearance of leukocytes in an acute resistance-training (RT) bout (10); furthermore, no effect was found on blood markers of muscle injury or subjective muscle pain. Thus, no current evidence shows that use of ibuprofen contributes to exercise tolerance

or influences physiological markers for muscle injury or subjective muscle pain.

2. Objectives

On the other hand, considering that athletes regularly consume NSAIDs for ergogenic benefit and that the literature is scarce on this subject, we investigated whether naproxen enhances neuromuscular performance. We hypothesized that naproxen ingestion would have a beneficial effect on neuromuscular outcomes when consumed prior to a RT session.

3. Methods

3.1. Sample

Participants were a convenience sample of 11 resistance-trained men (5.2 ± 5.0 years' experience) selected from bodybuilding gyms in the city of Lavras-MG. All participants signed an informed consent (TCLE) approved by the Ethics Committee of the Federal University of Lavras (under CAAE protocol number: 38090314.0.0000.5148) and according to the Declaration of Helsinki.

To be accepted into the study, participants were required to be males from 18 to 30 years of age with at least 1 year of strength-training experience. All prospective participants completed a questionnaire (12), and those who had a chronic medical condition that could create an unnecessary risk during the exercise test or who reported using some type of NSAID were excluded from the study. Participants reported free from use of anabolic steroids were instructed to avoid ingestion of supplements or pharmaceutical drugs on days of the experiment. Table 1 presents participants' physical characteristics.

Table 1. Physical Characteristics of Study Participants (N = 11)

Variable	Value
Age	24.6 \pm 5.5
Height, cm	178.7 \pm 5.2
Weight, Kg	80.3 \pm 9.0
BMI, Kg/m ²	27.63 \pm 4.8
Body fat, %	22.0 \pm 3.4
Body fat free, %	77.9 \pm 3.4
Total body water, %	57.8 \pm 2.8
1 RM, Kg	98.1 \pm 23.1

Abbreviations: 1 RM, 1 repetition maximum; BMI, body mass index.

3.2. Experimental Protocol

This study employed a crossover, randomized, double-blind, placebo-controlled design, conducted in the laboratory of human movement studies (LEMOH) at the Physical Education Department of the Federal University of Lavras (DEF-UFLA). Participants visited the laboratory on three separate occasions with a 24-hour interval between the first and second sessions and 144 hours between the second and third sessions as per previous studies (13, 14). Randomization was conducted using Microsoft Excel.

The first session included signing the TCLE, randomization of the sample, anthropometric measurements, and 1 repetition maximum (1 RM) testing. Session 2 included strength training and ingestion of a naproxen tablet or placebo. For strength-training sessions, participants consumed a tablet containing either naproxen (tablet 1) or placebo (tablet 2) 1 hour prior to the session. At the beginning of strength-training sessions, participants performed a 30-second warm-up at 30% of 1 RM on the horizontal bench press, followed by a 1-minute rest interval. Subsequently, three maximal sets were performed of the horizontal bench press at 90% of 1 RM, with each set separated by a 2-minute rest interval. Cadence was set at 45 radians per second (2 seconds) for the concentric action and 45 radians per second (2 seconds) for the eccentric action (2/AC for 2/AE) time as controlled by Metronome Plus software. Twenty-four hours after the training session, participants assessed their level of DOMS through the visual analog scale (VAS). Participants reported this measurement daily at the same time each day. DOMS data were recorded via daily telephone contact between participants and research staff. In session 3, participants crossed over, so those who had taken tablet 1 in the first session took tablet 2 in this session and vice versa. Figure 1 provides a schematic of the experimental design.

3.3. Drug Administration

Pharmacological treatment was administered 1 hour prior to each participant's strength-training session. A 144-hour crossover interval was provided between conditions for administration of naproxen and the placebo. Volunteers ingested a naproxen capsule (500 mg) or a placebo capsule (microcrystalline cellulose) with the same shape, color, weight, odor, and taste as naproxen 500 mg. A single investigator was responsible for randomization and distribution of capsules to participants. Volunteers and researchers had no knowledge of capsules' contents.

3.4. Anthropometry

Anthropometric measures were performed according to Guedes (15), using the following criteria: (A) not having taken diuretic medication in the last 7 days; (B) having




Figure 1. Experimental design

fasted for at least 4 h; (C) not having consumed alcoholic beverages in the last 48 h; (D) not having performed intense physical activity in the last 24 h; (E) urinating at least 30 min before the measurement; and, (F) remaining in absolute rest for at least 8 - 10 min in the supine position before having measurements taken. Height and body mass data were measured in the orthostatic position using a Welmy® scale and stadiometer. The percentage of adipose tissue and fat-free mass was estimated with a Quantum BIA-II® tetrapolar bioimpedance apparatus (RJL Systems, Inc. Clinton: MI, USA) with 3M® electrodes (model 2223BR). For the right foot, the distal electrode was affixed at the base of the middle toe, while the proximal electrode was affixed between the distal epiphyses of the tibia and fibula. For the right hand, the distal electrode was affixed on the base of the middle finger, and the proximal electrode was affixed on the styloid process. All procedures were performed at the same time of day at a controlled temperature of 22 °C and 75% relative humidity. Data obtained from apparatus's resistance and reactance were transferred to the software Body Composition 2.1, where the sample's collected data on height, body mass, and wrist circumference had already been recorded. Participants' body fat percentage was estimated from these data.

3.5. 1 Repetition Maximum Test

The 1 RM test is characterized by the greatest possible load that a participant can lift for one repetition of an exercise (12, 16, 17). Once participants were acclimated to the equipment and taught the necessary techniques certified

by the strength and conditioning specialist, they participated in the 1 RM test. Determination for 1 RM was made for the horizontal bench press as follows: First, participants performed two warm-up sets of two to five repetitions. The load for these sets was established at approximately 50% to 80% of their estimated 1 RM. These warm-ups were followed by sets of increasingly heavier weights with inter-set rest intervals of 5 minutes until a 1 RM weight was established for each participant. The same researcher monitored all 1 RM tests to help ensure good validity (12).

3.6. Strength-Training Session

Exercise intensity and time were adapted from Correa et al. (11). After a 30-second warm-up at 30% of 1 RM in the horizontal bench press exercise, participants from both groups began the test session at 6:00 P.M. Each participant performed three sets of the horizontal bench press exercise at 90% of 1 RM until concentric failure, with a 1-minute inter-set rest interval. Cadence was set at 45 radians per second (2 seconds) for the concentric action and 45 radians per second (2 seconds) for the eccentric action (2/AC for 2/AE) as controlled by Metronome Plus software. Environmental factors such as the noise level (82 dB), temperature (19.0 ± 1.0 °C), humidity (40% - 50%), and comfort were strictly controlled. Participants were encouraged to achieve as many repetitions as possible in each set until concentric failure.

3.7. Workload

Workload for each set was calculated as the product of repetitions and load. To determine total workload, we summed means of the three sets. The following equations were used for determination of workload:

$$\begin{aligned} \text{Repetitions} \times \text{load set} &= \text{workload set} \\ \text{Total workload} &= \sum \text{workload sets} \end{aligned}$$

3.8. Fatigue Index

The fatigue index (FI) was employed to identify the strength loss rate by the equation that Sforzo and Touey proposed (18):

$$FI = \frac{TS(\text{set } 1) - TS(\text{set } 3)}{TS(\text{set } 1)} \times 100\%$$

FI = fatigue index and TS = total strength (lifted load \times number of repetitions during sets).

3.9. Delayed Onset Muscle Soreness (DOMS)

The visual analog scale (VAS) was used to measure perceived DOMS. The scale is designed to express pain from a straight line with numerical values having a range of 0 to 10, where 0 represents “no pain”, 5 represents “average pain”, and 10 represents “unbearable pain”. The evaluator instructed participants to demarcate the relative value of their perception of pain in the VAS.

3.10. Statistical Analysis

Descriptive statistics (mean \pm standard deviation) were used to present all data. Four separate repeated measures analyses of variance were used to compare the number of repetitions, DOMS, workload, and FI for treatment (naproxen versus placebo) and time. With respect to time, the number of repetitions, workload, and FI analysis encompassed the number of sets ($n = 3$ time points), while for DOMS, the analysis encompassed time points in hours ($n = 6$ time points). Where indicated, post hoc analysis was conducted through the Bonferonni test for statistically significant effects. Statistical analyses were performed using IBM SPSS statistics software 23 (IBM Corp., Armonk, NY). Results were considered significant at $\alpha \leq 0.05$.

4. Results

A significant main effect was observed for time ($P < 0.001$), with a decrease in the number of repetitions noted across all sets for both treatments ($P < 0.05$). There was no statistical difference between treatments ($P = 0.067$) and no interactions between conditions ($P = 0.32$), although a large relative difference of 44.89% was noted in the third set favoring naproxen (Table 2).

Table 2. Number of Repetitions Performed Across Sets

Group	1st Set	2nd Set	3rd Set
Naproxen	4.73 \pm 2.10	4.09 \pm 2.07	3.55 \pm 1.36
Placebo	4.82 \pm 2.22	3.73 \pm 1.55	2.45 \pm 1.29
Percentage	-1.86	+9.65	+44.89




Figure 2. Delayed onset muscle soreness

As shown in Figure 2, perceived DOMS was lower in the naproxen group across all time points, but differences were not statistically significant between treatments ($P = 0.10$). There was a significant main effect for time, with reductions in DOMS noted from 24 to 48h ($P = 0.016$), 48 h to 96 h (0.033), and 72 h to 120 h (0.017).

Table 3 displays comparison of workload in the three sets between and within groups, and total workload between groups. There was a significant effect for treatment ($P = 0.42$), with naproxen showing greater total workload across sets compared to placebo. There was also a main effect of time ($P = 0.002$), with workload significantly decreasing on each successive set, irrespective of treatment ($P < 0.05$).

Table 4 shows comparison of the fatigue index between groups during the three sets. A main effect for time was noted, with a statistically significant difference observed between the second and third sets compared to set 1 ($P = 0.003$). No main effect for treatment ($P = 0.14$) or interaction ($P = 0.072$) was noted.

5. Discussion

The present study showed that use of naproxen prior to a strength-training session can positively affect performance and alleviate markers of DOMS and muscle fatigue. Findings may be related to the study participants' high level of physical conditioning. Trained participants require large workloads to generate mechanical overload, which can result in considerable damage to muscle structures (membranes, Z-line, sarcolemma, T-tubules, and myofibrils). According to Grgic et al., higher loads cause

Table 3. Comparison of the Workload in the Three Sets

Group	1st Set	2nd Set	3rd Set	Total
Naproxen	410.23 ± 176.43	352.47 ± 174.12	308.29 ± 127.78	1071.00 ± 439.80 ^a
Placebo	409.09 ± 190.63	320.07 ± 133.37	208.14 ± 127.89	937.30 ± 393.60
Percentage	-0.24	-10	-32	-12

^a Significantly different from placebo.

Table 4. Fatigue Index (FI)

Group	FI 1 × 2	FI 1 × 3	FI 2 × 3
Naproxen, %	13.25	18.56	5.79 ^a
Placebo, %	4.72	52.39	29.09

^a FI 2 × 3 naproxen group × placebo group P (0.02)

greater wear and micro injury and thus necessitate greater recovery (19).

A recent double-blind, placebo-controlled study that provided 1.2 g of ibuprofen showed no statistical benefit of NSAID consumption in the number of repetitions between sets and in total training volume in the bench press and squat exercises at a load of 65% of 1 RM in young men (11). The load used in that study was low; in contrast, the load in our study was high, with potential to provoke a greater inflammatory process and neural fatigue. A recent systematic review found evidence that NSAID ingestion reduces markers of neuromuscular damage after sets performed to concentric failure (20, 21). Moreover, the intake of 1 g of an NSAID also improved quadriceps torque after an intermittent exercise protocol (21, 22). These findings are consistent with those observed in our study, which found that when training with high loads, the number of repetitions, total volume of work, and rate of fatigue improved, indicating that NSAIDs can be ergogenic when consumed prior to strenuous exercise.

Evidence regarding use of NSAIDs to alleviate DOMS remains equivocal, with some studies showing little to no efficacy of ibuprofen (4, 10, 23). For naproxen, Bourgeois et al. showed that a 500-mg dose taken pre- and post-exercise did not decrease perceived DOMS (24). This result is somewhat in contrast to the findings of Brewer et al. (25), who reported that a 440-mg dose of naproxen reduced the response of the metabolite prostaglandin F_{2α} (PGF_{2α}). Prostaglandin F_{2α} (PGF_{2α}) is directly related to the post-exercise inflammatory process, and, consequently, its decreased activation would seemingly lead to lower sensation of DOMS (25, 26). However, given that muscle damage was not measured directly, this finding should be taken with circumspection (25). In the present study, participants reported their perceived DOMS for 1 week, and no sig-

nificant differences were found in this outcome. Possibly, the use of VAS, an indirect measurement tool, does not necessarily reflect changes in underlying causes of DOMS. In addition, although naproxen has a longer action time than ibuprofen (27), neither has been found to decrease DOMS significantly in most athletes.

One novel aspect of this study is investigation into naproxen's effects on fatigue indices. Although results did not reach statistical significance, our findings demonstrated that naproxen use resulted in decreased FI, with marked relative differences in the second and third sets between treatments (33.8% and 23.3%, respectively). The literature remains equivocal as to the inflammatory process pursuant to high and low loads; recent studies suggest that training volume, rather than intensity, primarily drives exercise-induced inflammation (28, 29). The naproxen-mediated decrease in FI conceivably occurs via inhibition of synthesis of prostaglandins, endogenous substances produced in the inflammatory process, upon blocking activation of isoenzymes constitutive of cyclooxygenase 1 (COX1) and inductive cyclooxygenase 2 (COX2) (1, 5, 30-32). Large standard deviations noted in this variable indicate that any beneficial effects may be specific to the individual.

The study had several limitations that must be considered when attempting to draw practical conclusions. First, we did not measure metabolic parameters such as lactate, CK, and myoglobin, thus impeding our ability to define potential mechanisms responsible for NSAIDs' positive effects on acute RT performance. Moreover, our findings cannot be generalized to conclude that all classes of NSAIDs induce an ergogenic effect. Accordingly, future studies should seek to determine potential ergogenic effects of different doses of this class of drugs. In view of these considerations, this study's conclusions are restricted to the dose of one 500-mg tablet of naproxen taken 1 hour before exercise and to the population studied (young, resistance-trained men).

5.1. Conclusions

The present study demonstrated that ingestion of naproxen had an ergogenic effect on an acute strength-training bout. It should be emphasized that this appears to

be the first study to evaluate this drug's effect on strength-training performance. Novel studies controlling other training variables and providing different doses are necessary for further clarification of naproxen's effects during exercise.

From a practical standpoint, NSAID use prior to a training session may help increase the number of repetitions and training volume in a RT session. Further experiments should be conducted to verify whether chronic NSAID use continues to enhance performance over time or whether beneficial effects decrease or perhaps become refractory.

Footnotes

Authors' Contribution: Moises Silvestre de Azevedo Martins and Sandro Fernandes da Silva conceived and designed research. Moises Silvestre de Azevedo Martins, Gabriel G Zanetti and Sandro Fernandes da Silva conducted experiments. Reury F P Bacurau and Brad J Schoenfeld analyzed data. Moises Silvestre de Azevedo Martins, Brad J Schoenfeld, Gabriel G Zanetti, Reury F P Bacurau and Sandro Fernandes da Silva wrote the manuscript. All authors read and approved the manuscript.

Conflict of Interests: The authors declare no conflicts of interest in the writing and preparation of this article.

Ethical Approval: The article was approved by the Ethics Committee under protocol 13480213.7.0000.5148.

Funding/Support: It is not declared by the authors.

References

1. Batlouni M. [Nonsteroidal anti-inflammatory drugs: Cardiovascular, cerebrovascular and renal effects]. *Arq Bras Cardiol*. 2010;**94**(4):556-63. Portuguese. [PubMed: 20498929].
2. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. *Inflamm Res*. 1998;**47** Suppl 2:S78-87. [PubMed: 9831328].
3. Da Silva ER, De Rose EH, Ribeiro JP, Sampedro LB, Devos DV, Ferreira AO, et al. Non-steroidal anti-inflammatory use in the XV pan-American games (2007). *Br J Sports Med*. 2011;**45**(2):91-4. doi: 10.1136/bjism.2009.065342. [PubMed: 19955164].
4. Schoenfeld BJ. The use of nonsteroidal anti-inflammatory drugs for exercise-induced muscle damage: Implications for skeletal muscle development. *Sports Med*. 2012;**42**(12):1017-28. doi: 10.2165/11635190-000000000-00000. [PubMed: 23013520].
5. Schoenfeld BJ. Non-steroidal anti-inflammatory drugs may blunt more than pain. *Acta Physiol (Oxf)*. 2018;**222**(2). doi: 10.1111/apha.12990. [PubMed: 29117467].
6. De Rose EH, Feder MG, Pedroso PR, Guimarães AZ. Referred use of medication and dietary supplements in athletes selected for doping control in the South-American games. *Rev Bras Med Esporte*. 2006;**12**(5):239-42. doi: 10.1590/s1517-86922006000500003.
7. Hakkinen K, Alen M, Kraemer WJ, Gorostiaga E, Izquierdo M, Rusko H, et al. Neuromuscular adaptations during concurrent strength and endurance training versus strength training. *Eur J Appl Physiol*. 2003;**89**(1):42-52. doi: 10.1007/s00421-002-0751-9. [PubMed: 12627304].
8. Kyrolainen H, Avela J, McBride JM, Koskinen S, Andersen JL, Sipila S, et al. Effects of power training on muscle structure and neuromuscular performance. *Scand J Med Sci Sports*. 2005;**15**(1):58-64. doi: 10.1111/j.1600-0838.2004.00390.x. [PubMed: 15679573].
9. Faulkner JA, Brooks SV, Opitck JA. Injury to skeletal muscle fibers during contractions: Conditions of occurrence and prevention. *Phys Ther*. 1993;**73**(12):911-21. [PubMed: 8248299].
10. Vella L, Markworth JF, Paulsen G, Raastad T, Peake J, Snow J, et al. Ibuprofen ingestion does not affect markers of post-exercise muscle inflammation. *Front Physiol*. 2016;**7**(86):1-9. doi: 10.3389/fphys.2016.00086. [PubMed: 27064890]. [PubMed Central: PMC4809889].
11. Correa CS, Cadore EL, Baroni BM, Silva ER, Bijoldo JM, Pinto RS, et al. Effects of prophylactic anti-inflammatory non-steroidal ibuprofen on performance in a session of strength training. *Rev Bras Med Esporte*. 2013;**19**(2):116-9. doi: 10.1590/s1517-86922013000200009.
12. Shariat A, Kargarfard M, Danaee M, Bahri Mohd Tamrin S. Intensive resistance exercise and circadian salivary testosterone concentrations among young male recreational lifters. *J Strength Cond Res*. 2015;**29**(1):151-8. doi: 10.1519/jsc.0000000000000632. [PubMed: 25051005].
13. Lecomte JM, Lacroix VJ, Montgomery DL. A randomized controlled trial of the effect of naproxen on delayed onset muscle soreness and muscle strength. *Clin J Sport Med*. 1998;**8**(2):82-7. [PubMed: 9641434].
14. Choi HG, Jeon JY, Kwak SS, Kim H, Jin C, Im YJ, et al. Pharmacokinetic comparison study of a combination containing 500 mg of Naproxen and 20 mg of Esomeprazole: A randomized, single-dose, 2-way crossover, open-label study in healthy Korean men. *Clin Ther*. 2015;**37**(1):83-93. doi: 10.1016/j.clinthera.2014.11.004. [PubMed: 25482305].
15. Guedes DP. Clinical procedures used for analysis of the body composition. *Rev Bras Cineantropom Desempenho Hum*. 2013;**15**(1). doi: 10.5007/1980-0037.2013v15n1p113.
16. Reynolds JM, Gordon TJ, Robergs RA. Prediction of one repetition maximum strength from multiple repetition maximum testing and anthropometry. *J Strength Cond Res*. 2006;**20**(3):584-92. doi: 10.1519/JR-15304.1. [PubMed: 16937972].
17. Baechle TR, Earle RW. Essentials of strength training and conditioning (NSCA). In: Everett H, editor. *Biomechanics of Resistance Exercise*. Champaign: Human Kinetics; 2008. p. 394-400.
18. Sforzo GA, Touey PR. Manipulating exercise order affects muscular performance during a resistance exercise training session. *J Strength Cond Res*. 1996;**10**(1):20-4. doi: 10.1519/00124278-199602000-00004.
19. Grgic J, Homolak J, Mikulic P, Botella J, Schoenfeld BJ. Inducing hypertrophic effects of type I skeletal muscle fibers: A hypothetical role of time under load in resistance training aimed at muscular hypertrophy. *Med Hypotheses*. 2018;**112**:40-2. doi: 10.1016/j.mehy.2018.01.012. [PubMed: 29447936].
20. Morelli KM, Brown LB, Warren GL. Effect of NSAIDs on recovery from acute skeletal muscle injury: A systematic review and meta-analysis. *Am J Sports Med*. 2018;**46**(1):224-33. doi: 10.1177/0363546517697957. [PubMed: 28355084].
21. Lundberg TR, Howatson G. Analgesic and anti-inflammatory drugs in sports: Implications for exercise performance and training adaptations. *Scand J Med Sci Sports*. 2018;**28**(11):2252-62. doi: 10.1111/sms.13275. [PubMed: 30102811].
22. Morgan PT, Bowtell JL, Vanhatalo A, Jones AM, Bailey SJ. Acute acetaminophen ingestion improves performance and muscle activation during maximal intermittent knee extensor exercise. *Eur J Appl Physiol*. 2018;**118**(3):595-605. doi: 10.1007/s00421-017-3794-7. [PubMed: 29332237]. [PubMed Central: PMC5805811].
23. Candia-Luján R, De Paz-Fernández JA. Son efectivos los antiinflamatorios no esteroides en el tratamiento del dolor muscular tardío? *CienciaUAT*. 2014;**9**(1):76. doi: 10.29059/cienciauat.v9i1.630.

24. Bourgeois J, MacDougall D, MacDonald J, Tarnopolsky M. Naproxen does not alter indices of muscle damage in resistance-exercise trained men. *Med Sci Sports Exerc.* 1999;**31**(1):4-9. [PubMed: 9927002].
25. Brewer CB, Bentley JP, Day LB, Waddell DE. Resistance exercise and naproxen sodium: Effects on a stable PGF₂α metabolite and morphological adaptations of the upper body appendicular skeleton. *Inflammopharmacology.* 2015;**23**(6):319-27. doi: 10.1007/s10787-015-0248-x. [PubMed: 26289996].
26. Markworth JF, Vella LD, Figueiredo VC, Cameron-Smith D. Ibuprofen treatment blunts early translational signaling responses in human skeletal muscle following resistance exercise. *J Appl Physiol (1985).* 2014;**117**(1):20-8. doi: 10.1152/jappphysiol.01299.2013. [PubMed: 24833778].
27. Schiff M, Minic M. Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee. *J Rheumatol.* 2004;**31**(7):1373-83. [PubMed: 15229960].
28. Mangine GT, Hoffman JR, Wang R, Gonzalez AM, Townsend JR, Wells AJ, et al. Resistance training intensity and volume affect changes in rate of force development in resistance-trained men. *Eur J Appl Physiol.* 2016;**116**(11-12):2367-74. doi: 10.1007/s00421-016-3488-6. [PubMed: 27744584].
29. Figueiredo VC, de Salles BF, Trajano GS. Volume for muscle hypertrophy and health outcomes: The most effective variable in resistance training. *Sports Med.* 2018;**48**(3):499-505. doi: 10.1007/s40279-017-0793-0. [PubMed: 29022275].
30. Hilário MOE, Terreri MT, Len CA. [Nonsteroidal anti-inflammatory drugs: Cyclooxygenase 2 inhibitors]. *J Pediatr.* 2006;**82**(5):S206-12. Portuguese. doi: 10.1590/s0021-75572006000700011.
31. Michelin ADF, Ferreira AAP, Bitar VG, Lopes LC. Renal toxicity of the selective cyclooxygenase-2 inhibitors: Celecoxib and rofecoxib. *Rev Cienc Med.* 2006;**15**(4):321-32.
32. Park JY, Pillinger MH, Abramson SB. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. *Clin Immunol.* 2006;**119**(3):229-40. doi: 10.1016/j.clim.2006.01.016. [PubMed: 16540375].